AzTrials
AzTrials

PregnancyCFOPNCT02677558

The Impact of Obesity on Cardiac Function in Pregnancy

An observational study of Pregnancy and Obesity, run by University of Cape Town at 1 site in South Africa.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine the impact of obesity in pregnancy on maternal cardiac function. For this, morbidly obese term pregnant women (study group) and term pregnant women of normal weight are assessed by transthoracic echocardiography. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Pregnancy, Obesity
What is being tested?
Transthoracic Echocardiography
How many people
80 participants
Where
1 siteSouth Africa
Study dates
Jan 2016to Mar 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Healthy obese pregnant, non-labouring women at term who fulfil the inclusion criteria will be recruited into the study group. As controls, healthy non-obese non-labouring term pregnant women will be recruited. Controls will be matched for age and ethnicity.

Who may be able to join

  • BMI >/= 35kg/m2 for study group and </= 30kg/m2 for control group
  • uncomplicated singleton term pregnancy

Who cannot join

  • any comorbidities affecting cardiac function
  • receiving any cardiovascular drugs
  • in active labour
  • inability to give informed consent

Trial locations and contacts

1 site in 1 country.

South Africa1 site
  • University of Cape Town; Groote Schuur Hospital

    Cape Town, Western Cape, 7935

Other trials in South Africa

About this study

The purpose of this study is to determine the impact of obesity in pregnancy on maternal cardiac function. For this, morbidly obese term pregnant women (study group) and term pregnant women of normal weight are assessed by transthoracic echocardiography.

Read the detailed description

INTRODUCTION:

The prevalence of obesity is increasing to alarming rates worldwide. The impact of obesity on cardiovascular health is well documented, but much less is known about the impact of obesity in pregnancy on maternal cardiac function. The aim of the current study is to investigate how the cardiovascular system of morbidly obese women adapts to the circulatory changes associated with pregnancy.

BACKGROUND:

Overweight and obesity is a major threat to global health. In 2013, 36.9% of all men and 38% of all women worldwide were overweight or obese as defined by a BMI of ≥25 kg/m2 or of ≥30 kg/m2 respectively. According to a systematic analysis for the Global Burden of Disease Study 2013, South Africa ranks third in a list of the world's most obese nations behind the United States and Mexico. The prevalence of overweight (BMI ≥25kg/m2) and obesity (BMI ≥30kg/m2) combined in the age group above 20 years is estimated to be 38.8% for men and 69.3% for women in South Africa. In the age group below 20 years, it is 18.8% for boys and 26.3% for girls. 42% of women above the age of 20 years and 9.6% of girls below 20 years are considered obese.

The impact of obesity on the structure and the function of the heart is well documented. Obesity is strongly associated with risk factors for the development of atherosclerotic disease such as hypertension, hyperlipidaemia, and diabetes. In addition, there is evidence that obesity in itself can lead to structural and functional changes in the heart. The following changes are commonly encountered in obesity:

  1. Left ventricular remodelling: Many studies report that obesity is associated with an increase in left ventricular mass (LV mass). LV mass is commonly indexed against the body surface area (BSA). In the setting of significant obesity, LV mass/BSA is often normal or reduced, because the BSA increases more than the LV mass. Many investigators therefore choose to index LV mass to lean body mass, height or height raised to the power of 2.76. Recent studies agree that both wall thickness and cavity size seem to be increased in obesity, but wall thickness is increased to a greater extent, leading to a concentric pattern of left ventricular hypertrophy in obesity.
  2. Right ventricular size: Only few studies have looked at the changes in the right ventricle in obesity. Wong et al. found mild increase in RV cavity size and wall thickness in uncomplicated obesity.
  3. Left atrial size: Obesity is associated with an increase in left atrial size. Hypertension, volume overload and diastolic filling abnormalities commonly lead to an increase in left atrial size. All are commonly present in obesity.
  4. Left ventricular systolic function: Recent studies report that LV ejection fraction is preserved in obesity or even above normal. There are, however subclinical contractile abnormalities which can already be found in obese children and adolescents comparable to those found in adult obese subjects.
  5. Left ventricular diastolic function: The most common finding is that isovolumetric relaxation time is prolonged in obesity. Reduced tissue doppler velocities have also been reported.
  6. Right ventricular function: Reduced RV systolic and diastolic function have been reported in individuals with a BMI ≥35kg/m2.

It is well established that obesity in pregnancy is a associated with an increased risk for thromboembolism, preeclampsia, postpartum haemorrhage, caesarean section and instrumental delivery. The impact of obesity during pregnancy might however reach even further. A well conducted retrospective study published in Hypertension this year found an association between obesity in pregnancy and premature mortality and morbidity from major cardiovascular events later in life. It is thought that the cardio-metabolic changes of obese pregnancy potentially unmask the patients at risk for cardiovascular events later in life.

Transthoracic echocardiography can detect subclinical alterations in cardiac structure and function. It is non-invasive and does not bear any risk for the mother or the baby. A routine assessment of the haemodynamic status in all obese pregnant women therefore has the potential to establish which women are at increased risk for haemodynamic complications during pregnancy and/or later in life. However, there have been only a limited number of studies on the haemodynamic changes in morbidly obese parturients as assessed by transthoracic echocardiography.

STUDY OBJECTIVES:

Hypothesis:

  1. We hypothesise that cardiac dysfunction as determined by transthoracic echocardiography occurs more frequently in morbidly obese pregnant women than in pregnant women with normal BMI.
  2. We hypothesise that the severity of the observed cardiac dysfunction correlates with the degree of obesity.

Aims:

  1. To quantify the incidence of systolic and diastolic dysfunction and cardiac structural abnormalities in obese pregnant women at term.
  2. To quantify the incidence of systolic and diastolic dysfunction and cardiac structural abnormalities in healthy term pregnant women with a normal BMI.
  3. To quantify the severity of cardiac dysfunction and remodelling in obese pregnant women at term.

METHODOLOGY

Study design:

This prospective case control study will be carried out at Groote Schuur Maternity Clinic and Mowbray Maternity Hospital in Cape Town, South Africa.

Characteristics of study population:

We are aiming to recruit 40 obese pregnant, non-labouring women at term who fulfil the inclusion criteria. As controls, 40 healthy non-obese non-labouring term pregnant women will be recruited. Controls will be matched for age and ethnicity.

Recruitment:

Patients for the study group and the control group will be recruited from the antenatal clinic and antenatal wards.

Informed Consent:

Written informed consent will be obtained from all participants. Forms will be available in English and explained to the participants. The interview will be conducted in the participant's language of choice and a translator will assist with interpretation if required.

Data collection:

After enrolment in the study and informed consent, study patients and controls will undergo an echocardiographic examination as described below.

Demographic Data:

At the time point of enrolment, the following data will be recorded for all participants according to standard care in pregnancy:

  • age
  • gestational age and parity
  • ethnicity
  • height and weight
  • blood pressure

Echocardiographic assessment:

A full standard echocardiographic assessment according to the protocol of the British Society of Echocardiography14 will be performed by an experienced investigator (passed European Echocardiography Examination), except subcostal views which are technically not feasible in pregnant women. In addition, a detailed right heart examination will be performed.

The examination will take place in the left lateral position to improve image quality and prevent obstruction of the inferior vena cava. A GE echocardiography machine will be used. For each acquisition, 3 cardiac cycles will be stored and analysed offline (after the examination) with Centricity Electronic Medical Records software developed by GE at a workstation at the Department of Anaesthesia/Cardiology. All echocardiographic assessments and offline analysis will be performed by one experienced investigators without blinding. Thereafter a second experienced investigator will review the images independently offline.

Schedule:

Data collection is planned to take place over a duration of 3 months in 2016.

Risks and Benefits:

Transthoracic echocardiography is a non-invasive procedure and safe for both the mother and the baby. No risk will arise due to participation in the study. The timing of the study will not interfere with routine clinical care.

If a cardiac condition is noted during the examination or any of the echocardiographic findings require a change to the planned care, this will be communicated to the patient's medical team without delay.

Participation in the study will therefore bring an additional clinical benefit to the mother at no additional risk.

Data handling and Confidentiality:

All demographic data pertaining to a participant will be collected on a standardised form.

Each participant will be assigned a unique study number. The echocardiography data will be stored on the GE echocardiography machine using this number only, with no identifying information. From here the data will be exported to the hospital based echocardiography data system for analysis (Centricity Electronic Medical Records). The participants are thus de-linked from their hospital admission numbers and confidentiality is protected. The records can only be accessed with an assigned login from Groote Schuur hospital that will only be available to the approved users of the Centricity system.

A record of hospital admission numbers will be maintained to correlate echocardiography data with clinical data and allow the patient's medical team to be informed of any relevant pathology that may impact patient care. The Principal Investigator will have access to the record log and this information will not be made available outside the University of Cape Town.

Study records that identify a patient are kept confidential as required by law. Privacy regulations provide safeguards for privacy, security and authorised access. Except when required by law, no data will identify the patient in the study records. The data collected remains the intellectual property of the University of Cape Town.

Data Analysis:

Demographic and obstetrics data will be displayed as mean and standard deviation, median with interquartile ranges, or number and percentage as appropriate. Analysis of recorded transthoracic echocardiography variables and heart rate and blood pressure will be made using analysis of variance (ANOVA) and a General Linear Model with significant p value defined as < 0.05 after performing F tests on the collected data. Pearson's correlation will be used to assess the strength of the linear relationship between variables. The null hypothesis will be rejected if critical p < 0.05 for each of the variables.

Conditions
Pregnancy, Obesity
Being tested
Transthoracic Echocardiography
Keywords
Pregnancy, Obesity, Echocardiography
Medical subject headings
Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transthoracic EchocardiographyOther

    Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.

Study groups in NCT02677558
Study groupRoleWhat they receive
CFOP obeseTransthoracic Echocardiography in pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of greater or equal 40kg/m2 at the time point of inclusion into the study. Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia.
Receives: Other: Transthoracic Echocardiography
CFOP controlTransthoracic Echocardiography pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of less or equal 30kg/m2 at the time point of inclusion into the study. Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia
Receives: Other: Transthoracic Echocardiography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of systolic and diastolic cardiac dysfunction in morbidly obese pregnant women compared to term pregnant women of normal weight through transthoracic echocardiography.

    Measured: At inclusion into study

Secondary outcomes (1)
  1. Correlation of degree of cardiac dysfunction in morbidly obese term pregnant women with BMI

    Measured: At inclusion into study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Feb 2016 (estimated)
  2. Study startJan 2016
  3. Primary completionMar 2016
  4. Study completionMar 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Other
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02677558
Sponsor's protocol ID
021/2016
Acronym
CFOP
Status last verified
May 2021
First submitted
4 Feb 2016
Last updated
14 May 2021
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Publications

  • Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008 Apr;88(2):389-419. doi: 10.1152/physrev.00017.2007.

    PubMed 18391168
  • Wong CY, O'Moore-Sullivan T, Leano R, Hukins C, Jenkins C, Marwick TH. Association of subclinical right ventricular dysfunction with obesity. J Am Coll Cardiol. 2006 Feb 7;47(3):611-6. doi: 10.1016/j.jacc.2005.11.015. Epub 2006 Jan 18.

    PubMed 16458145
  • Powell BD, Redfield MM, Bybee KA, Freeman WK, Rihal CS. Association of obesity with left ventricular remodeling and diastolic dysfunction in patients without coronary artery disease. Am J Cardiol. 2006 Jul 1;98(1):116-20. doi: 10.1016/j.amjcard.2006.01.063. Epub 2006 May 6.

    PubMed 16784933
  • Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B, Davila-Roman VG. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol. 2004 Apr 21;43(8):1399-404. doi: 10.1016/j.jacc.2003.10.062.

    PubMed 15093874
  • de Simone G, Kizer JR, Chinali M, Roman MJ, Bella JN, Best LG, Lee ET, Devereux RB; Strong Heart Study Investigators. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. Am J Hypertens. 2005 Feb;18(2 Pt 1):191-6. doi: 10.1016/j.amjhyper.2004.08.032.

    PubMed 15752946
  • de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension. 1994 May;23(5):600-6. doi: 10.1161/01.hyp.23.5.600.

    PubMed 8175168
  • Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation. 2004 Nov 9;110(19):3081-7. doi: 10.1161/01.CIR.0000147184.13872.0F. Epub 2004 Nov 1.

    PubMed 15520317
  • Reidy J, Russell R. CMACE 2006-2008. Int J Obstet Anesth. 2011 Jul;20(3):208-12. doi: 10.1016/j.ijoa.2011.04.004. No abstract available.

    PubMed 21641202
  • Lee KK, Raja EA, Lee AJ, Bhattacharya S, Bhattacharya S, Norman JE, Reynolds RM. Maternal Obesity During Pregnancy Associates With Premature Mortality and Major Cardiovascular Events in Later Life. Hypertension. 2015 Nov;66(5):938-44. doi: 10.1161/HYPERTENSIONAHA.115.05920. Epub 2015 Sep 14.

    PubMed 26370890
  • Dennis AT, Castro JM, Ong M, Carr C. Haemodynamics in obese pregnant women. Int J Obstet Anesth. 2012 Apr;21(2):129-34. doi: 10.1016/j.ijoa.2011.11.007. Epub 2012 Feb 11.

    PubMed 22326199
  • Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki T, AlBuhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W, Anwari P, Banerjee A, Barquera S, Basu S, Bennett DA, Bhutta Z, Blore J, Cabral N, Nonato IC, Chang JC, Chowdhury R, Courville KJ, Criqui MH, Cundiff DK, Dabhadkar KC, Dandona L, Davis A, Dayama A, Dharmaratne SD, Ding EL, Durrani AM, Esteghamati A, Farzadfar F, Fay DF, Feigin VL, Flaxman A, Forouzanfar MH, Goto A, Green MA, Gupta R, Hafezi-Nejad N, Hankey GJ, Harewood HC, Havmoeller R, Hay S, Hernandez L, Husseini A, Idrisov BT, Ikeda N, Islami F, Jahangir E, Jassal SK, Jee SH, Jeffreys M, Jonas JB, Kabagambe EK, Khalifa SE, Kengne AP, Khader YS, Khang YH, Kim D, Kimokoti RW, Kinge JM, Kokubo Y, Kosen S, Kwan G, Lai T, Leinsalu M, Li Y, Liang X, Liu S, Logroscino G, Lotufo PA, Lu Y, Ma J, Mainoo NK, Mensah GA, Merriman TR, Mokdad AH, Moschandreas J, Naghavi M, Naheed A, Nand D, Narayan KM, Nelson EL, Neuhouser ML, Nisar MI, Ohkubo T, Oti SO, Pedroza A, Prabhakaran D, Roy N, Sampson U, Seo H, Sepanlou SG, Shibuya K, Shiri R, Shiue I, Singh GM, Singh JA, Skirbekk V, Stapelberg NJ, Sturua L, Sykes BL, Tobias M, Tran BX, Trasande L, Toyoshima H, van de Vijver S, Vasankari TJ, Veerman JL, Velasquez-Melendez G, Vlassov VV, Vollset SE, Vos T, Wang C, Wang X, Weiderpass E, Werdecker A, Wright JL, Yang YC, Yatsuya H, Yoon J, Yoon SJ, Zhao Y, Zhou M, Zhu S, Lopez AD, Murray CJ, Gakidou E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 Aug 30;384(9945):766-81. doi: 10.1016/S0140-6736(14)60460-8. Epub 2014 May 29.

    PubMed 24880830

Questions about this trial

What is this clinical trial studying?

An observational study of Pregnancy and Obesity, run by University of Cape Town at 1 site in South Africa.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 May 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of systolic and diastolic cardiac dysfunction in morbidly obese pregnant women compared to term pregnant women of normal weight through transthoracic echocardiography. (time frame: At inclusion into study). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02677558, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in